Seeking Alpha
 

AMAG Pharmaceuticals, Inc. (AMAG)

- NASDAQ
  • Fri, Aug. 21, 10:16 AM
    • Evoke Pharma (EVOK +2.7%) initiated with Buy rating and $13 (197% upside) price target by Brean Capital.
    • Biocept (BIOC +7.5%) initiated with Buy rating and $4 (86% upside) price target by H.C. Wainwright.
    • Juno Therapeutics (JUNO -3.8%) initiated with Outperform rating and $73 (94% upside) price target by FBR.
    • Neos Therapeutics (NEOS -2.1%) initiated with Outperform rating and $35 (52% upside) price target by RBC Capital Markets.
    • Trovagene (TROV +1.3%) initiated with Outperform rating and $9 (64% upside) price target by Leerink.
    • AMAG Pharmaceuticals (AMAG -0.4%) upgraded to Buy from Restricted with a price target of $80 (31% upside) by Jefferies.
    • Spectranetics (SPNC -0.4%) upgraded to Strong Buy from Buy with a $24 (46% upside) price target by Needham.
    | Fri, Aug. 21, 10:16 AM | Comment!
  • Wed, Aug. 12, 4:16 PM
    • AMAG Pharmaceuticals (NASDAQ:AMAG) prices its $500M aggregate principal amount of 7.875% Senior Notes due 2023 at par. The offering was upsized $50M from its original plan announced on August 5. Closing date is August 17.
    • Net proceeds will fund the Cord Blood Registry acquisition.
    • Previously: AMAG Pharma initiates $450M debt offering (Aug. 5)
    | Wed, Aug. 12, 4:16 PM | Comment!
  • Wed, Aug. 5, 10:59 AM
    • AMAG Pharmaceuticals (AMAG +2.1%) commences an offering of $450M aggregate principal amount Senior Notes due 2023. Net proceeds will fund its previously announced takeover of Cord Blood Registry.
    • Price and terms have yet to be announced.
    | Wed, Aug. 5, 10:59 AM | Comment!
  • Thu, Jul. 30, 8:29 PM
    • AMAG Pharmaceuticals (NASDAQ:AMAG) prices its public offering of 3.15M shares of common stock at $63.75 per share. Underwriters over-allotment is an additional 472.5K shares. Closing date is August 5.
    • Today's close was $64.77.
    | Thu, Jul. 30, 8:29 PM | Comment!
  • Thu, Jul. 30, 6:43 AM
    • AMAG Pharmaceuticals (NASDAQ:AMAG) commences a $200M public offering of common stock. Underwriters over-allotment is an additional 15% of the number of shares offered. Price, volume and terms have yet to be announced.
    • Net proceeds will fund the expansion and diversification of its product portfolio, to pay various fees and expenses associated with the Cord Blood Registry acquisition and general corporate purposes.
    | Thu, Jul. 30, 6:43 AM | Comment!
  • Thu, Jul. 23, 7:09 AM
    • AMAG Pharmaceuticals (NASDAQ:AMAG): Q2 EPS of $1.12 misses by $0.01.
    • Revenue of $90.32M (+264.2% Y/Y) misses by $3.73M.
    • Press Release
    | Thu, Jul. 23, 7:09 AM | Comment!
  • Wed, Jul. 22, 5:30 PM
  • Mon, Jun. 29, 2:33 PM
    • AMAG Pharmaceuticals (AMAG -2.9%) acquires Cord Blood Registry (CBR), the world's largest stem cell collection and storage firm, for $700M. CBR houses over 600K umbilical cord blood and tissue stem cell units representing over 50% of the privately stored cord units in the U.S.
    • In 2014, CBR generated ~$126M in revenues and $45M in non-GAAP EBITDA. 2015's top line is projected to be slightly above $126M. Expense synergies should be ~$15M per year.
    • The deal, expected to close in Q3, is being funded with debt.
    | Mon, Jun. 29, 2:33 PM | 2 Comments
  • Fri, Jun. 12, 12:17 PM
    • AMAG Pharmaceuticals (AMAG -1.5%) initiated with Hold rating and $75 (10% upside) price target by Deutsche Bank.
    • Supernus Pharmaceuticals (SUPN +9.5%) initiated with Buy rating and $30 (70% upside) price target by SunTrust Robinson Humphrey.
    • Plasmatech Biopharmaceuticals (PTBI -2.7%) initiated with Buy rating and $16 (118% upside) price target by Roth Capital.
    • Horizon Pharma (HZNP -0.4%) initiated with Overweight rating and $38 (19% upside) price target by Morgan Stanley.
    • Depomed (DEPO -2.1%) initiated with Equal Weight rating and $23 (10% upside) price target by Morgan Stanley.
    • Community Health Systems (CYH +0.5%) initiated with Outperform rating and $65 (19% upside) price target by Wedbush.
    • HCA Holdings (HCA -0.1%) initiated with Outperform rating and $93 (11% upside) price target by Wedbush.
    • LifePoint Health (LPNT -0.2%) initiated with Neutral rating and $80 (5% upside) price target by Wedbush.
    • HealthSouth (HLS) initiated with Neutral rating and $46 (3% downside risk) price target by Wedbush.
    • Adeptus Health (ADPT -0.4%) initiated with Overweight rating and $106 (26% upside) price target by KeyBanc.
    • Universal Health Services (UHS -0.1%) initiated with Neutral rating and $141 (7% upside) price target by Janney Capital.
    • Owens & Minor (OMI -0.2%) initiated with Sector Perform rating and $35 (3% upside) price target by RBC Capital.
    • Henry Schein (HSIC -0.6%) initiated with Outperform rating and $165 (16% upside) price target by RBC Capital.
    | Fri, Jun. 12, 12:17 PM | 5 Comments
  • Thu, May 28, 8:48 AM
    • AMAG Pharmaceuticals (NASDAQ:AMAG) receives a Completed Response Letter (CRL) from the FDA regarding its manufacturing supplement seeking approval for a single-dose vial of Makena (hydroxyprogesterone caproate injection). The prescription hormone, used to lower the risk of preterm birth, is currently sold in a multi-dose vial.
    • The FDA requests additional information related to the manufacturing procedures for the single-dose vial at a third party manufacturer.
    • The company plans to launch the single-dose vial in Q4.
    | Thu, May 28, 8:48 AM | 1 Comment
  • Wed, May 6, 12:57 PM
    • The following healthcare-related stocks trade at least 500K shares/day, have a minimum market cap of $1B, show increasing mutual fund ownership, reported an after-tax margin of at least 15% last quarter and reported growth of cash flow from operations at least 50% greater than EPS growth last year:
    • (ABMD -2.6%)(ALGN -0.8%)(AMAG)(EBS +0.7%)(KANG -1.3%)(SHPG -0.3%)(XON +0.8%)
    • This is not a list of Buy recommendations, but rather a targeted list of firms that may be suitable for more in-depth research.
    | Wed, May 6, 12:57 PM | 3 Comments
  • Tue, May 5, 7:19 AM
    • AMAG Pharmaceuticals (NASDAQ:AMAG): Q1 EPS of $1.17 beats by $0.29.
    • Revenue of $89.51M (+329.5% Y/Y) beats by $4.85M.
    • Press Release
    | Tue, May 5, 7:19 AM | Comment!
  • Mon, May 4, 5:30 PM
  • Wed, Feb. 25, 7:53 PM
    • AMAG Pharmaceuticals (NASDAQ:AMAG) prices its public offering of 3,977,272 shares of common stock at $44 per share. Underwriters over-allotment is an additional 596,590 shares. Closing date is March 3.
    • Net proceeds will fund general corporate purposes.
    | Wed, Feb. 25, 7:53 PM | Comment!
  • Tue, Feb. 24, 5:08 PM
    • AMAG Pharmaceuticals (NASDAQ:AMAG) commences a public offering of ~$125M in common stock. Underwriters over-allotment is an additional 15% of the number of shares offered. The price has yet to be announced.
    | Tue, Feb. 24, 5:08 PM | Comment!
  • Mon, Feb. 9, 4:16 PM
    • AMAG Pharmaceuticals (NASDAQ:AMAG): Q4 EPS of $4.67 may not be comparable to consensus of $0.30.
    • Revenue of $53.3M (+145.5% Y/Y) beats by $0.61M.
    • Press Release
    | Mon, Feb. 9, 4:16 PM | 1 Comment
Visit Seeking Alpha's
AMAG vs. ETF Alternatives
Company Description
AMAG Pharmaceuticals Inc is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The Company markets Makena; Feraheme, Injection for Intravenous (IV) use; and MuGard, Mucoadhesive Oral Wound Rinse.